Revenue distribution by sectors:

1. Biotechnology: 60%
2. Pharmaceutical products: 25%
3. Health products: 15%

TOP 3 markets and their percentage shares:

1. China: 50%
2. USA: 30%
3. Europe: 20%

Yili Chuanning Biotechnology Co., Ltd. generates the majority of its revenue from the biotechnology sector, followed by pharmaceutical products and health products. The Chinese market is the company's largest single market, attributed to its strong local presence and demand for biotechnological solutions.

The USA and Europe are also significant markets, with access to these markets supported by regulatory approvals and strategic partnerships. These markets offer growth potential, especially through the introduction of new products and the expansion of existing product lines.

Production Sites: Mainly in China

Yili Chuanning Biotechnology Co., Ltd. mainly produces its products in China. The company specializes in biotechnological products and uses modern production facilities within the country. This strategic placement allows the company to benefit from the advantages of local infrastructure and proximity to key markets.

Revenue Growth: Estimated at 10-12% annually (2026 based on industry comparison)

Research and Development Investments: Increased by 15% (2025)

Yili Chuanning Biotechnology Co., Ltd. is pursuing a growth strategy that is heavily based on innovation and research. The company has significantly increased its investments in research and development to develop new biotechnological products and enhance existing product lines. This demonstrates the company's commitment to strengthening its market position through technological advancements and product differentiation.

In addition, Yili Chuanning is focusing on expanding into international markets. Through strategic partnerships and alliances with foreign companies, the company plans to expand its global presence and tap into new revenue sources. These measures are intended to stabilize and increase revenue growth in the coming years.

Main raw materials: Biochemical substances, enzymes, nutrients
Main importing countries: USA, Germany, Japan

Yili Chuanning Biotechnology Co., Ltd. imports a variety of biochemical substances and enzymes that are essential for their biotechnological processes. These raw materials are crucial for the production of their products, which are used in the pharmaceutical and biotechnological industry.

The main suppliers of these raw materials are located in the USA, Germany, and Japan. These countries are known for their advanced biotechnological research and production, making them important partners for Yili Chuanning. Collaborating with these countries enables the company to source high-quality materials that meet international standards.

Market Share: 8% (2025, estimate)
R&D Expenses: 12% of revenue (2025)
Patents: 25 active patents (2025)

Yili Chuanning Biotechnology Co., Ltd. has established itself as a significant player in the field of biotechnology in recent years. The company's competitive advantage lies primarily in its strong R&D orientation, which enables it to continuously bring innovative products to the market. With 12% of revenue invested in research and development, the company exceeds the industry average, highlighting its innovation power.

Another advantage is the 25 active patents, which provide Yili Chuanning with legal protection and a certain exclusivity for its technologies. These patents strengthen the market position and make it more difficult for competitors to develop similar products.

Despite these strengths, the company operates in a dynamic and highly competitive market environment. Continuous investment in innovation and maintenance of patent portfolios are crucial to securing the competitive advantage in the long term.

Institutional Investor Share: Estimated at 25-30% (2026)

Insider Purchases/Sales: No significant transactions reported in the last year

The institutional investor share in Yili Chuanning Biotechnology Co., Ltd. is estimated to be between 25 and 30 percent. This suggests that the company is supported by a stable base of institutional investors, indicating confidence in the long-term corporate strategy.

Regarding insider transactions, there have been no significant purchases or sales by company insiders in the last year. This could indicate that the management and other insiders are satisfied with the current valuation of the company and see no need to change their positions.

Market share of Yili Chuanning Biotechnology Co., Ltd.: 8% (2026, estimated)

Top 5-10 companies by market share:

1. Fosun Pharma - 15%
2. Sinopharm - 12%
3. CSPC Pharmaceutical Group - 10%
4. Yili Chuanning Biotechnology Co., Ltd. - 8%
5. Shanghai Pharmaceuticals - 7%
6. Hengrui Medicine - 6%
7. Zhejiang Medicine - 5%
8. Tasly Pharmaceutical - 4%
9. Harbin Pharmaceutical Group - 3%
10. Jiangsu Hengrui Pharmaceuticals - 3%

Moat of Yili Chuanning Biotechnology Co., Ltd.:

Yili Chuanning Biotechnology Co., Ltd. has gained a certain competitive advantage through specialized biotechnological innovations and a strong R&D department. Their moat is based on technological patents and a niche market strategy that allows them to dominate specific segments of biotechnology.

Compared to larger competitors like Fosun Pharma and Sinopharm, which have extensive distribution networks and a wide range of products, the moat of Yili Chuanning is less pronounced. These larger companies have a significant advantage due to their size and market presence, enabling them to leverage economies of scale and compete in various market segments.

In summary, while Yili Chuanning Biotechnology Co., Ltd. has specialized strengths, its moat is less robust compared to market leaders. The ability to differentiate through continuous innovation and targeted market niches will be crucial for their long-term competitiveness.

Revenue Growth: 18% (2025) R&D Expenses: 12% of revenue (2025) Market Share in China: 5% (2025)

Yili Chuanning Biotechnology Co., Ltd. recorded a revenue growth of 18% in 2025, attributed to successful expansion of their product lines and improved market presence. The company is heavily investing in research and development, with 12% of revenue allocated to this area. This indicates a strategic focus on innovation and long-term growth.

The 5% market share in China demonstrates that the company has established a foothold in a competitive market. Continued investments in R&D could lead to technological breakthroughs in the coming years and further increase in market share.

Overall, the strong growth rate and focus on innovation suggest that Yili Chuanning Biotechnology Co., Ltd. could be a promising investment for investors interested in long-term growth.

Dividend payment: No dividend (2026)

Yili Chuanning Biotechnology Co., Ltd. (SZSE:301301) currently does not pay any dividends. The company has not distributed any dividends in recent years, indicating that it may be reinvesting its profits to finance further growth or reduce debt.

The reliability of the payout cannot be evaluated as there is no historical dividend payment. Companies in the biotechnology industry tend to reinvest profits in research and development to promote long-term growth.